

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Shanghai Haohai Biological Technology Co., Ltd.\***

**上海昊海生物科技股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 6826)**

### **AMENDMENTS TO THE ARTICLES OF ASSOCIATION**

The amendments of the articles of association (the “**Articles of Association**”) of Shanghai Haohai Biological Technology Co., Ltd.\* (the “**Company**”) was approved by the meeting of the board of directors of the Company (the “**Board**”) held on 24 March 2023. The Board was authorized to approve the amendments to the Articles of Association pursuant to the 2021 Repurchase Mandate (as defined below) and the 2022 Repurchase Mandate (as defined below).

This announcement is made by the Company pursuant to Rule 13.51(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

References are made to the Company’s resolutions regarding the granting of a general mandate to the Board to repurchase H shares of the Company (the “**H Shares**”) approved at the Company’s 2020 annual general meeting, the 2021 first A shareholders’ class meeting and the 2021 first H shareholders’ class meeting convened on 11 June 2021 (the “**2021 Repurchase Mandate**”); and the Company’s resolutions regarding the granting of a general mandate to the Board to repurchase the H Shares approved at the Company’s 2021 annual general meeting, the 2022 second A shareholders’ class meeting and the 2022 second H shareholders’ class meeting convened on 29 June 2022 (the “**2022 Repurchase Mandate**”).

Pursuant to the 2021 Repurchase Mandate, the Company repurchased a total of 1,692,100 H Shares during the period from 30 December 2021 to 17 January 2022 and cancelled the relevant repurchased H Shares on 7 July 2022. Pursuant to the 2022 Repurchase Mandate, the Company repurchased a total of 2,859,000 H Shares during the period from 5 September 2022 to 8 November 2022 and cancelled the relevant repurchased H Shares on 14 February 2023.

After cancellation of all of the repurchased H shares above, the total share capital of the Company was reduced from 175,822,100 shares to 171,271,000 shares, and the registered capital of the Company was reduced from RMB175,822,100 to RMB171,271,000. At the meeting of the Board held on 24 March 2023, the Board considered and approved, among others, the proposal to amend the Articles of Association in accordance with such changes in the total share capital and registered capital of the Company. The Board was also authorized by the 2021 Repurchase Mandate and 2022 Repurchase Mandate to carry out cancellation procedures for the repurchased shares, reduce registered capital, make corresponding amendments to the Articles of Association in respect of the changes in the total share capital and shareholding structure, etc., and to carry out relevant statutory registrations and filing procedures within and outside of the People’s Republic of China (the “**PRC**”). In view of the above, these amendments to the Articles of Association will not be submitted once again for consideration and approval at the general meeting of the Company.

The amendments to the Articles of Association are as follows:

No.	Existing Articles	Revised Articles
1	<p><b>Article 18</b></p> <p>Upon establishment of the Company, as approved by the securities regulatory authorities under the State Council and the Hong Kong Stock Exchange, the Company issued 40,045,300 ordinary shares through initial public offering, all are H shares.</p> <p>.....</p> <p>Upon obtaining approval at the Company’s 2020 first extraordinary general meeting, 2020 first A shareholders’ class meeting and 2020 first H shareholders’ class meeting, the Company repurchased and cancelled 638,700 H shares. Upon obtaining approval at the Company’s 2019 annual general meeting, 2020 second A shareholders’ class meeting and 2020 second H shareholders’ class meeting, the Company repurchased and cancelled 1,384,500 H shares. After cancellation of the respective repurchased H shares, the share capital structure of the Company is as follows: the total share capital is 175,822,100 shares, of which 137,800,000 are A shares, representing 78.375% of the ordinary share capital of the Company, and 38,022,100 are H shares, representing 21.625% of the ordinary share capital of the Company.</p>	<p><b>Article 18</b></p> <p>Upon establishment of the Company, as approved by the securities regulatory authorities under the State Council and the Hong Kong Stock Exchange, the Company issued 40,045,300 ordinary shares through initial public offering, all are H shares.</p> <p>.....</p> <p>Upon obtaining approval at the Company’s 2020 first extraordinary general meeting, 2020 first A shareholders’ class meeting and 2020 first H shareholders’ class meeting, the Company repurchased and cancelled 638,700 H shares. Upon obtaining approval at the Company’s 2019 annual general meeting, 2020 second A shareholders’ class meeting and 2020 second H shareholders’ class meeting, the Company repurchased and cancelled 1,384,500 H shares. After cancellation of the respective repurchased H shares, the share capital structure of the Company is as follows: the total share capital is 175,822,100 shares, of which 137,800,000 are A shares, representing 78.375% of the ordinary share capital of the Company, and 38,022,100 are H shares, representing 21.625% of the ordinary share capital of the Company.</p>

No.	Existing Articles	Revised Articles
		<p><u>Upon obtaining approval at the Company's 2020 annual general meeting, 2021 first A shareholders' class meeting and 2021 first H shareholders' class meeting, the Company repurchased and cancelled 1,692,100 H shares. Upon obtaining approval at the Company's 2021 annual general meeting, 2022 second A shareholders' class meeting and 2022 second H shareholders' class meeting, the Company repurchased and cancelled 2,859,000 H shares. After cancellation of the respective repurchased H shares, the share capital structure of the Company is as follows: the total share capital is 171,271,000 shares, of which 137,800,000 are A shares, representing 80.457% of the ordinary share capital of the Company, and 33,471,000 are H shares, representing 19.543% of the ordinary share capital of the Company.</u></p>
2	<p><b>Article 21</b></p> <p>The registered capital of the Company is RMB175,822,100.</p>	<p><b>Article 21</b></p> <p>The registered capital of the Company is <u>RMB171,271,000.</u></p>

Save for the above amendments to the Articles of Association, other provisions of the Articles of Association will remain unchanged. The above amendments to the Articles of Association shall become effective on 24 March 2023.

The English version of the above amendments to the Articles of Association is an unofficial translation of its Chinese version. In case of any discrepancies, the Chinese version shall prevail.

By order of the Board  
**Shanghai Haohai Biological Technology Co., Ltd.\***  
*Chairman*  
**Hou Yongtai**

Shanghai, the PRC, 24 March 2023

*As at the date of this announcement, the executive directors of the Company are Dr. Hou Yongtai, Mr. Wu Jianying, Ms. Chen Yiyi and Mr. Tang Minjie; the non-executive directors of the Company are Ms. You Jie and Mr. Huang Ming; and the independent non-executive directors of the Company are Mr. Guo Yongqing, Mr. Jiang Zhihong, Mr. Su Zhi, Mr. Yang Yushe and Mr. Zhao Lei.*

\* For identification purpose only